Flu-v

Flu-v is a synthetic universal flu vaccine candidate offering long-lasting protection across a broad spectrum of influenza which could be given to a much broader population.

hVIVO plc, announced positive results for the primary endpoint, following completion of the analysis of samples by National Institute of Allergy and Infectious Diseases (NIAID) and additional results from the Phase IIb viral challenge study of FLU-v.